Ignite Creation Date:
2025-12-25 @ 3:31 AM
Ignite Modification Date:
2025-12-26 @ 2:13 AM
Study NCT ID:
NCT01662505
Status:
COMPLETED
Last Update Posted:
2018-07-30
First Post:
2012-08-08
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)
Sponsor:
Boehringer Ingelheim
Organization:
Study Overview
Official Title:
An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia
Status:
COMPLETED
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate safety, tolerability, maximum tolerated dose of volasertib in Japanese patients with AML
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: